Abstract
Emodin is a plant-derived natural compound with potential anti-cancer/tumor properties. In this study, we have evaluated the therapeutic efficacy of emodin as an anti-lymphoma drug in vivo in the Swiss Albino mice induced with Dalton Ascitic lymphoma (DAL). The Swiss Albino mice were induced with lymphoma by injecting the DAL cells intraperitonially and treated with the emodin or a standard drug methotrexate or a vehicle. Emodin has shown a significant therapeutic efficacy in controlling the overall DAL pathology and this was determined through gross pathology, serology, hematology, and histopathological readouts. Emodin reduced the tumor weight, volume, WBC count, and liver damage biomarkers like ALP and AST. It further reduced the inflammation at the portal areas in the liver and its associated inflammation scores. In summary, our findings show that the emodin has shown its therapeutic efficacy in controlling lymphoma in vivo highlighting its efficacy as an anti-lymphoma drug. Furthermore, the in silico analysis has shown that emodin as a potential drug candidate for lymphoma based on the Lipinski's rule of 5 and molecular docking studies.